Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Biofrontera Inc BFRI

Healthcare

Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial... see more

Add To Watchlist

Recent & Breaking News (NDAQ:BFRI)

Biofrontera Inc. Announces Resignation of CEO

Accesswire May 12, 2023

Biofrontera Inc. Announces New Secured Line of Credit up to $6.5 Million

Accesswire May 11, 2023

Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer Prevention

Accesswire May 9, 2023

Biofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023

Accesswire April 28, 2023

Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)

Accesswire April 26, 2023

Biofrontera Inc. Makes Transformative Investment in Its' Dermatology Salesforce

Accesswire March 27, 2023

Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting

Accesswire March 17, 2023

CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results

Accesswire March 9, 2023

Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results

Accesswire March 8, 2023

Biofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023

Accesswire March 2, 2023

Biofrontera Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

Accesswire February 22, 2023

Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

Accesswire January 9, 2023

Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022

Accesswire January 9, 2023

Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders

GlobeNewswire December 16, 2022

Biofrontera Inc. to Participate in Benchmark's 11th Annual Discovery One-on-One Investor Conference

GlobeNewswire November 30, 2022

BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022

GlobeNewswire November 28, 2022

Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

GlobeNewswire November 21, 2022

Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update

GlobeNewswire November 14, 2022

Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022

GlobeNewswire November 10, 2022

Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG

GlobeNewswire November 8, 2022